Skip to main content

Table 2 Results of univariate survival analysis

From: Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer

Characteristic Baseline model
(N = 323)
Chemotherapy response-based model (N = 233)
HR 95% CI p value HR 95% CI p value
Gender (female vs male) 1.45 1.10–1.92 0.008 1.49 1.09–2.05 0.011
Age (≤56 vs > 56) 1.01 1.00–1.03 0.012 1.22 0.90–1.66 0.199
KPS (70 ~ 80 vs 90 ~ 100) 0.57 0.43–0.77 < 0.001 0.45 0.33–0.63 < 0.001
Smoke (No vs Yes) 1.32 1.00–1.74 0.047 1.41 1.03–1.94 0.034
Ascites (No vs Yes) 1.46 1.08–1.96 0.012 1.54 1.11–2.16 0.011
Baseline WBC (≤ 6.39 vs > 6.39) 1.63 1.25–2.13 < 0.001 1.41 1.04–1.91 0.027
Baseline N (≤ 0.665 vs > 0.665) 1.60 1.23–2.09 0.001 1.68 1.24–2.29 0.001
Baseline LDH (≤159 vs > 159) 1.38 1.06–1.80 0.018 1.14 0.84–1.54 0.402
Baseline TB (≤11.4 vs>11.4) 1.45 1.11–1.89 0.006 1.43 1.06–1.94 0.021
Baseline Alb (≤ 40.5 vs > 40.5) 0.76 0.58–1.00 0.049 0.81 0.59–1.09 0.166
Baseline CEA (≤7.32 vs > 7.32) 1.47 1.13–1.92 0.005 1.44 1.06–1.95 0.019
Baseline CA 19–9 (≤1453 vs > 1453) 1.81 1.38–2.37 < 0.001 1.72 1.26–2.34 0.001
Change in CEA level at week 6   NI     
 Decrease      Ref  
 No change or increase     1.39 1.02–1.91 0.039
Change in CA19–9 level at week 6   NI     
 Decrease      Ref  
 No change or increase     1.69 1.23–2.31 0.001
Albumin at week 6 (≤39.0 vs>39.0)   NI   0.67 0.49–0.91 0.010
TB at week 6 (≤11.3 vs>11.3)   NI   1.36 1.01–1.85 0.047
CEA at week 6 (≤7.97 vs>7.97)   NI   1.58 1.17–2.14 0.003
CA 19–9 at week 6 (≤790.7 vs>790.7)   NI   1.99 1.46–2.73 < 0.001
Initial response to chemotherapy   NI     
 Non-PD      Ref  
 PD     3.07 2.17–4.35 < 0.001